SUPPLEMENT

Q2 2021 — Sales of Key Products/Franchises

Q2 2021PDF · 6 pages218 KB
REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US 	675	$ 	627 	7.7% 	7.7% 	- 	1,274	$ 	1,316 	-3.2% 	-3.2% 	-
Intl 	633 	522 	21.2% 	10.4% 	10.8% 	1,208 	1,181 	2.3% 	-4.7% 	7.0%
WW 	1,307 	1,149 	13.8% 	8.9% 	4.9% 	2,482 	2,497 	-0.6% 	-3.9% 	3.3%
SKIN HEALTH / BEAUTY
US 	659 	536 	23.0% 	23.0% 	- 	1,293 	1,195 	8.2% 	8.2% 	-
Intl 	511 	471 	8.4% 	1.4% 	7.0% 	1,040 	929 	12.0% 	6.8% 	5.2%
WW 	1,170 	1,007 	16.2% 	12.9% 	3.3% 	2,333 	2,124 	9.8% 	7.6% 	2.2%
ORAL CARE
US 	165 	170 	-3.1% 	-3.1% 	- 	328 	346 	-5.2% 	-5.2% 	-
Intl 	260 	227 	14.6% 	6.7% 	7.9% 	514 	446 	15.3% 	10.2% 	5.1%
WW 	426 	397 	7.0% 	2.5% 	4.5% 	843 	792 	6.3% 	3.5% 	2.8%
BABY CARE
US 	97 	96 	0.8% 	0.8% 	- 	193 	188 	2.4% 	2.4% 	-
Intl 	290 	260 	11.5% 	6.6% 	4.9% 	583 	529 	10.2% 	9.0% 	1.2%
WW 	387 	356 	8.6% 	5.0% 	3.6% 	776 	717 	8.1% 	7.3% 	0.8%
WOMEN'S HEALTH
US 	3 	3 	-3.1% 	-3.1% 	- 	6 	7 	-16.0% 	-16.0% 	-
Intl 	227 	199 	14.2% 	9.2% 	5.0% 	446 	427 	4.5% 	3.1% 	1.4%
WW 	230 	202 	13.9% 	9.0% 	4.9% 	452 	434 	4.2% 	2.8% 	1.4%
WOUND CARE / OTHER
US 	153 	126 	20.9% 	20.9% 	- 	268 	245 	9.3% 	9.3% 	-
Intl 	64 	59 	7.3% 	-2.8% 	10.1% 	125 	111 	12.1% 	5.2% 	6.9%
WW 	216 	185 	16.6% 	13.4% 	3.2% 	393 	356 	10.2% 	8.0% 	2.2%
TOTAL CONSUMER HEALTH
US 	1,751 	1,557 	12.4% 	12.4% 	- 	3,362 	3,297 	2.0% 	2.0% 	-
Intl 	1,984 	1,739 	14.1% 	6.3% 	7.8% 	3,916 	3,624 	8.1% 	3.3% 	4.8%
WW 	3,735	$ 	3,296 	13.3% 	9.2% 	4.1% 	7,278	$ 	6,921 	5.2% 	2.7% 	2.5%
See footnotes at end of schedule
% Change 	% Change

-- 1 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
PHARMACEUTICAL SEGMENT (2,3) 2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
IMMUNOLOGY
US 	2,748	$ 	2,362 	16.4% 	16.4% 	- 	5,161	$ 	4,772 	8.2% 	8.2% 	-
Intl 	1,483 	1,161 	27.7% 	18.2% 	9.5% 	2,984 	2,389 	24.9% 	17.0% 	7.9%
WW 	4,231 	3,523 	20.1% 	17.0% 	3.1% 	8,145 	7,161 	13.7% 	11.1% 	2.6%
REMICADE
US 	540 	593 	-9.1% 	-9.1% 	- 	1,029 	1,218 	-15.6% 	-15.6% 	-
US Exports (4) 93 	133 	-30.0% 	-30.0% 	- 	150 	243 	-38.2% 	-38.2% 	-
Intl 	255 	208 	22.4% 	11.1% 	11.3% 	487 	464 	4.9% 	-1.7% 	6.6%
WW 	888 	935 	-5.1% 	-7.6% 	2.5% 	1,665 	1,925 	-13.5% 	-15.1% 	1.6%
SIMPONI / SIMPONI ARIA
US 	290 	256 	12.8% 	12.8% 	- 	545 	528 	3.2% 	3.2% 	-
Intl 	294 	289 	1.7% 	-3.8% 	5.5% 	601 	547 	9.8% 	4.5% 	5.3%
WW 	584 	546 	6.9% 	4.0% 	2.9% 	1,146 	1,075 	6.6% 	3.8% 	2.8%
STELARA
US 	1,496 	1,138 	31.4% 	31.4% 	- 	2,827 	2,355 	20.0% 	20.0% 	-
Intl 	778 	558 	39.2% 	28.6% 	10.6% 	1,595 	1,161 	37.3% 	28.1% 	9.2%
WW 	2,274 	1,697 	34.0% 	30.5% 	3.5% 	4,422 	3,516 	25.8% 	22.7% 	3.1%
TREMFYA
US 	325 	241 	35.0% 	35.0% 	- 	599 	428 	40.0% 	40.0% 	-
Intl 	155 	101 	52.3% 	41.1% 	11.2% 	298 	210 	41.8% 	31.8% 	10.0%
WW 	479 	342 	40.2% 	36.8% 	3.4% 	897 	638 	40.6% 	37.3% 	3.3%
OTHER IMMUNOLOGY
US 	5 	- 	* 	* 	- 	12 	- 	* 	* 	-
Intl 	1 	3 	-61.3% 	-67.9% 	6.6% 	3 	6 	-51.2% 	-53.9% 	2.7%
WW 	7 	3 	* 	* 	* 	15 	6 	* 	* 	*
INFECTIOUS DISEASES
US 	444 	416 	6.8% 	6.8% 	- 	956 	852 	12.2% 	12.2% 	-
Intl 	585 	463 	26.3% 	18.2% 	8.1% 	1,079 	946 	14.1% 	7.8% 	6.3%
WW 	1,028 	878 	17.1% 	12.8% 	4.3% 	2,035 	1,798 	13.2% 	9.9% 	3.3%
COVID-19 VACCINE
US 	51 	- 	* 	* 	- 	151 	- 	* 	* 	-
Intl 	113 	- 	* 	* 	- 	113 	- 	* 	* 	-
WW 	164 	- 	* 	* 	- 	264 	- 	* 	* 	-
EDURANT / rilpivirine
US 	9 	10 	-9.3% 	-9.3% 	- 	19 	22 	-10.9% 	-10.9% 	-
Intl 	253 	246 	2.8% 	-4.0% 	6.8% 	486 	458 	6.0% 	-1.7% 	7.7%
WW 	262 	256 	2.3% 	-4.2% 	6.5% 	505 	480 	5.2% 	-2.1% 	7.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	368 	379 	-3.2% 	-3.2% 	- 	748 	775 	-3.5% 	-3.5% 	-
Intl 	137 	130 	5.5% 	-5.9% 	11.4% 	303 	314 	-3.5% 	-8.5% 	5.0%
WW 	505 	510 	-1.0% 	-3.9% 	2.9% 	1,051 	1,089 	-3.5% 	-5.0% 	1.5%
OTHER INFECTIOUS DISEASES
US 	16 	25 	-36.2% 	-36.2% 	- 	37 	54 	-31.3% 	-31.3% 	-
Intl 	81 	87 	-6.2% 	-13.4% 	7.2% 	177 	174 	1.8% 	-3.0% 	4.8%
WW 	98 	113 	-13.0% 	-18.5% 	5.5% 	215 	229 	-6.1% 	-9.7% 	3.6%
% Change 	% Change

-- 2 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
NEUROSCIENCE
US 	842 	778 	8.0% 	8.0% 	- 	1,613 	1,526 	5.6% 	5.6% 	-
Intl 	967 	809 	19.6% 	13.1% 	6.5% 	1,916 	1,719 	11.5% 	6.3% 	5.2%
WW 	1,808 	1,587 	13.9% 	10.6% 	3.3% 	3,529 	3,245 	8.7% 	6.0% 	2.7%
CONCERTA / Methylphenidate
US 	35 	55 	-36.0% 	-36.0% 	- 	82 	107 	-23.1% 	-23.1% 	-
Intl 	127 	94 	33.7% 	25.6% 	8.1% 	250 	212 	17.5% 	11.1% 	6.4%
WW 	161 	149 	8.1% 	3.0% 	5.1% 	332 	320 	3.9% 	-0.3% 	4.2%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	645 	576 	11.9% 	11.9% 	- 	1,234 	1,120 	10.2% 	10.2% 	-
Intl 	380 	303 	25.1% 	15.9% 	9.2% 	756 	642 	17.7% 	9.9% 	7.8%
WW 	1,024 	879 	16.4% 	13.3% 	3.1% 	1,989 	1,762 	12.9% 	10.1% 	2.8%
RISPERDAL CONSTA
US 	72 	74 	-3.0% 	-3.0% 	- 	139 	150 	-7.5% 	-7.5% 	-
Intl 	84 	79 	6.4% 	0.2% 	6.2% 	173 	173 	0.4% 	-4.6% 	5.0%
WW 	155 	153 	1.9% 	-1.3% 	3.2% 	312 	323 	-3.3% 	-6.0% 	2.7%
OTHER NEUROSCIENCE
US 	91 	75 	20.9% 	20.9% 	- 	158 	150 	5.6% 	5.6% 	-
Intl 	377 	331 	13.8% 	10.0% 	3.8% 	738 	691 	6.7% 	4.3% 	2.4%
WW 	468 	406 	15.1% 	12.0% 	3.1% 	896 	841 	6.5% 	4.5% 	2.0%
ONCOLOGY
US 	1,462 	1,181 	23.7% 	23.7% 	- 	2,839 	2,356 	20.5% 	20.5% 	-
Intl 	2,073 	1,609 	28.8% 	19.8% 	9.0% 	4,266 	3,448 	23.7% 	16.2% 	7.5%
WW 	3,535 	2,791 	26.7% 	21.5% 	5.2% 	7,105 	5,804 	22.4% 	17.9% 	4.5%
DARZALEX
US 	770 	492 	56.7% 	56.7% 	- 	1,461 	955 	53.1% 	53.1% 	-
Intl 	663 	409 	62.1% 	50.3% 	11.8% 	1,337 	883 	51.4% 	42.3% 	9.1%
WW 	1,433 	901 	59.2% 	53.8% 	5.4% 	2,798 	1,838 	52.2% 	47.9% 	4.3%
ERLEADA
US 	193 	136 	41.5% 	41.5% 	- 	364 	255 	42.7% 	42.7% 	-
Intl 	109 	33 	* 	* 	* 	199 	57 	* 	* 	*
WW 	302 	170 	77.6% 	73.7% 	3.9% 	563 	313 	80.0% 	76.4% 	3.6%
IMBRUVICA
US 	454 	447 	1.7% 	1.7% 	- 	898 	879 	2.2% 	2.2% 	-
Intl 	662 	502 	31.9% 	22.1% 	9.8% 	1,342 	1,101 	21.9% 	14.2% 	7.7%
WW 	1,116 	949 	17.7% 	12.5% 	5.2% 	2,241 	1,980 	13.2% 	8.9% 	4.3%
ZYTIGA / abiraterone acetate
US 	21 	87 	-75.3% 	-75.3% 	- 	71 	226 	-68.5% 	-68.5% 	-
Intl 	542 	480 	12.8% 	5.4% 	7.4% 	1,130 	1,032 	9.5% 	2.5% 	7.0%
WW 	563 	568 	-0.8% 	-7.1% 	6.3% 	1,201 	1,258 	-4.5% 	-10.3% 	5.8%
OTHER ONCOLOGY
US 	23 	20 	18.8% 	18.8% 	- 	44 	42 	6.3% 	6.3% 	-
Intl 	97 	185 	-47.2% 	-49.6% 	2.4% 	258 	375 	-31.0% 	-34.3% 	3.3%
WW 	120 	204 	-40.9% 	-43.0% 	2.1% 	302 	416 	-27.3% 	-30.2% 	2.9%
% Change 	% Change

-- 3 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
PULMONARY HYPERTENSION
US 	595 	545 	9.0% 	9.0% 	- 	1,168 	1,031 	13.2% 	13.2% 	-
Intl 	275 	243 	13.5% 	7.9% 	5.6% 	563 	503 	12.1% 	6.7% 	5.4%
WW 	870 	789 	10.4% 	8.7% 	1.7% 	1,731 	1,534 	12.9% 	11.1% 	1.8%
OPSUMIT
US 	290 	256 	13.6% 	13.6% 	- 	562 	485 	15.9% 	15.9% 	-
Intl 	172 	150 	14.9% 	9.0% 	5.9% 	351 	310 	13.1% 	7.6% 	5.5%
WW 	463 	406 	14.1% 	11.9% 	2.2% 	913 	795 	14.8% 	12.7% 	2.1%
UPTRAVI
US 	268 	254 	6.0% 	6.0% 	- 	527 	466 	13.3% 	13.3% 	-
Intl 	45 	28 	54.9% 	42.9% 	12.0% 	91 	66 	36.8% 	27.4% 	9.4%
WW 	313 	282 	11.0% 	9.8% 	1.2% 	618 	532 	16.2% 	15.0% 	1.2%
OTHER PULMONARY HYPERTENSION
US 	36 	37 	-2.4% 	-2.4% 	- 	78 	81 	-3.0% 	-3.0% 	-
Intl 	59 	64 	-8.2% 	-10.3% 	2.1% 	122 	126 	-3.5% 	-6.3% 	2.8%
WW 	95 	101 	-6.1% 	-7.5% 	1.4% 	200 	207 	-3.3% 	-5.0% 	1.7%
CARDIOVASCULAR / METABOLISM / OTHER
US 	780 	837 	-6.9% 	-6.9% 	- 	1,579 	1,643 	-3.9% 	-3.9% 	-
Intl 	346 	347 	-0.3% 	-8.4% 	8.1% 	674 	701 	-3.8% 	-9.9% 	6.1%
WW 	1,126 	1,184 	-5.0% 	-7.3% 	2.3% 	2,253 	2,344 	-3.9% 	-5.7% 	1.8%
XARELTO
US 	569 	559 	1.8% 	1.8% 	- 	1,158 	1,086 	6.6% 	6.6% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	569 	559 	1.8% 	1.8% 	- 	1,158 	1,086 	6.6% 	6.6% 	-
INVOKANA / INVOKAMET
US 	96 	132 	-27.0% 	-27.0% 	- 	183 	249 	-26.6% 	-26.6% 	-
Intl 	64 	47 	33.8% 	22.1% 	11.7% 	127 	105 	20.3% 	12.2% 	8.1%
WW 	160 	179 	-10.9% 	-14.0% 	3.1% 	310 	354 	-12.6% 	-15.0% 	2.4%
PROCRIT / EPREX
US 	59 	70 	-16.3% 	-16.3% 	- 	121 	146 	-17.3% 	-17.3% 	-
Intl 	69 	66 	3.7% 	-4.5% 	8.2% 	133 	145 	-8.2% 	-14.1% 	5.9%
WW 	127 	136 	-6.6% 	-10.6% 	4.0% 	254 	291 	-12.8% 	-15.7% 	2.9%
OTHER
US 	57 	78 	-26.7% 	-26.7% 	- 	117 	163 	-27.8% 	-27.8% 	-
Intl 	214 	234 	-8.4% 	-15.7% 	7.3% 	415 	451 	-8.1% 	-13.7% 	5.6%
WW 	271 	312 	-13.0% 	-18.4% 	5.4% 	532 	614 	-13.3% 	-17.4% 	4.1%
TOTAL PHARMACEUTICAL
US 	6,869 	6,120 	12.2% 	12.2% 	- 	13,315 	12,181 	9.3% 	9.3% 	-
Intl 	5,730 	4,632 	23.7% 	15.4% 	8.3% 	11,483 	9,705 	18.3% 	11.4% 	6.9%
WW 	12,599	$ 	10,752 	17.2% 	13.6% 	3.6% 	24,798	$ 	21,886 	13.3% 	10.3% 	3.0%
See footnotes at end of schedule
% Change 	% Change

-- 4 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
MEDICAL DEVICES SEGMENT (2) 2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	475	$ 	255 	86.5% 	86.5% 	- 	909 	620 	46.7% 	46.7% 	-
Intl 	572 	335 	70.5% 	59.8% 	10.7% 	1,086 	697 	55.7% 	46.4% 	9.3%
WW 	1,046 	590 	77.4% 	71.3% 	6.1% 	1,995 	1,317 	51.5% 	46.5% 	5.0%
ORTHOPAEDICS
US 	1,323 	869 	52.3% 	52.3% 	- 	2,572 	2,119 	21.4% 	21.4% 	-
Intl 	904 	583 	55.1% 	43.2% 	11.9% 	1,768 	1,371 	29.0% 	20.2% 	8.8%
WW 	2,227 	1,451 	53.4% 	48.6% 	4.8% 	4,340 	3,489 	24.4% 	20.9% 	3.5%
HIPS
US 	234 	137 	70.5% 	70.5% 	- 	444 	343 	29.6% 	29.6% 	-
Intl 	159 	88 	78.6% 	64.3% 	14.3% 	305 	220 	38.3% 	28.6% 	9.7%
WW 	392 	226 	73.7% 	68.1% 	5.6% 	749 	563 	33.0% 	29.2% 	3.8%
KNEES
US 	210 	108 	94.3% 	94.3% 	- 	395 	322 	22.7% 	22.7% 	-
Intl 	140 	66 	* 	95.1% 	16.8% 	272 	196 	39.2% 	29.5% 	9.7%
WW 	350 	174 	* 	94.6% 	6.4% 	667 	517 	28.9% 	25.2% 	3.7%
TRAUMA
US 	447 	354 	26.0% 	26.0% 	- 	897 	761 	17.8% 	17.8% 	-
Intl 	263 	198 	32.7% 	22.7% 	10.0% 	545 	445 	22.5% 	14.4% 	8.1%
WW 	710 	553 	28.4% 	24.8% 	3.6% 	1,443 	1,207 	19.6% 	16.5% 	3.1%
SPINE, SPORTS & OTHER
US 	433 	270 	60.6% 	60.6% 	- 	836 	693 	20.7% 	20.7% 	-
Intl 	343 	230 	49.0% 	37.9% 	11.1% 	646 	510 	26.7% 	18.0% 	8.7%
WW 	776 	499 	55.3% 	50.2% 	5.1% 	1,482 	1,202 	23.2% 	19.6% 	3.6%
% Change 	% Change

-- 5 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER 	SIX MONTHS
2021 	2020 	Reported 	Operational (1) Currency 	2021 	2020 	Reported 	Operational (1) Currency
SURGERY
US 	1,035 	490 	* 	* 	- 	1,933 	1,334 	44.9% 	44.9% 	-
Intl 	1,487 	1,060 	40.2% 	30.6% 	9.6% 	2,961 	2,317 	27.8% 	20.4% 	7.4%
WW 	2,522 	1,551 	62.6% 	56.0% 	6.6% 	4,894 	3,651 	34.0% 	29.3% 	4.7%
ADVANCED
US 	459 	277 	65.4% 	65.4% 	- 	864 	658 	31.3% 	31.3% 	-
Intl 	708 	498 	42.2% 	32.5% 	9.7% 	1,421 	1,065 	33.4% 	25.6% 	7.8%
WW 	1,168 	775 	50.5% 	44.3% 	6.2% 	2,286 	1,723 	32.6% 	27.8% 	4.8%
GENERAL
US 	576 	213 	* 	* 	- 	1,069 	676 	58.1% 	58.1% 	-
Intl 	779 	562 	38.5% 	28.9% 	9.6% 	1,540 	1,252 	23.0% 	15.9% 	7.1%
WW 	1,354 	775 	74.7% 	67.8% 	6.9% 	2,608 	1,928 	35.3% 	30.7% 	4.6%
VISION
US 	467 	248 	88.3% 	88.3% 	- 	939 	687 	36.6% 	36.6% 	-
Intl 	716 	447 	60.0% 	53.7% 	6.3% 	1,389 	1,075 	29.2% 	24.6% 	4.6%
WW 	1,183 	695 	70.1% 	66.0% 	4.1% 	2,328 	1,762 	32.1% 	29.3% 	2.8%
CONTACT LENSES / OTHER
US 	352 	203 	73.3% 	73.3% 	- 	723 	549 	31.6% 	31.6% 	-
Intl 	517 	352 	47.0% 	41.9% 	5.1% 	1,003 	819 	22.5% 	18.5% 	4.0%
WW 	868 	554 	56.7% 	53.4% 	3.3% 	1,725 	1,368 	26.1% 	23.7% 	2.4%
SURGICAL
US 	115 	45 	* 	* 	- 	216 	138 	56.3% 	56.3% 	-
Intl 	199 	96 	* 	97.1% 	10.6% 	386 	256 	50.9% 	44.4% 	6.5%
WW 	314 	141 	* 	* 	* 	602 	394 	52.8% 	48.6% 	4.2%
TOTAL MEDICAL DEVICES
US 	3,299 	1,862 	77.2% 	77.2% 	- 	6,353 	4,760 	33.5% 	33.5% 	-
Intl 	3,679 	2,426 	51.6% 	41.9% 	9.7% 	7,204 	5,460 	31.9% 	24.5% 	7.4%
WW 	6,978	$ 	4,288 	62.7% 	57.2% 	5.5% 	13,557	$ 	10,220 	32.7% 	28.7% 	4.0%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change 	% Change

-- 6 of 6 --